Rituximab

Drug Profile

Rituximab

Alternative Names: IDEC-102; IDEC-C2B8; IDEC-C2B8-anti-CD20; MabThera; R 105; RG 105; Rituxan; Rituximab-EU; RO-452294

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Janssen Research & Development; Mayo Clinic; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Idiopathic thrombocytopenic purpura; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase III Diffuse large B cell lymphoma; Mantle-cell lymphoma; Pemphigus vulgaris; Transplant rejection
  • Phase II/III Neuromyelitis optica
  • Phase II B cell lymphoma; Glomerulonephritis
  • No development reported Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Immune thrombocytopenic purpura; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 01 Aug 2017 Zenyaku Kogyo initiates enrolment in a phase II trial for Diffuse large B-cell lymphoma and Follicular lymphoma(First-line therapy) in Japan (JapicCTI-173663)
  • 20 Jul 2017 Phase-I clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT03136497)
  • 02 Jul 2017 Roche completes the phase III MabRella trial for Non-Hodgkin's lymphoma (First-line therapy) in Spain (SC) (NCT01987505)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top